APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Objective
Primary: Part 1 (Phase Ib): To assess the safety and tolerability of APG-115 in combination with pembrolizumab including determination of the MTD and RP2D in patients with metastatic melanomas or solid tumors.
Part 2 (Phase II): To assess overall response rate of APG-115 in combination with pembrolizumab in the treatment of patients with unresectable or metastatic melanomas
